U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
(Exact name of small business issuer as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer ID No.) |
| (Address of principal executive offices) | (Zip Code) |
(
(Issuer’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| OTC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Material Event |
On November 1, 2022, Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. announced that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”).
| Item 7.01 | Regulation FD Disclosure |
Attached is a copy of a press release being issued by the Company relating to the above-referenced matter, a copy of which is attached as Exhibit as 99.1 and is hereby incorporated.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
| Number | Exhibit |
| 99.1 | Press Release |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Odyssey Health, Inc. | ||
| By: | /s/ Joseph Michael Redmond | |
| Joseph Michael Redmond Chief Executive Officer | ||
Date: November 1, 2022
| 2 |
Exhibit 99.1
Odyssey Health Inc. Files Full US Patent Application on
Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
Las Vegas, NV, November 1, 2022 — McapMediaWire —Odyssey Health, Inc. (OTC: ODYY) (the "Company" or "Odyssey"), announced that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As announced, Odyssey’s recently completed Phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination.
Odyssey designed the Nasal Device with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for quick and direct diffusion into the brain to treat central nervous system (“CNS”) injury, disease or disorder.
The Phase I study used Odyssey’s novel Nasal Device to deliver Odyssey’s concussion drug, PRV-002, and to determine the safety of its PRV-002 concussion drug. The PRV-002 concussion drug-Nasal Device combination was well-tolerated in forty (40) healthy human volunteers. The study documented no Nasal Device failures.
“We were very pleased with the functionality and performance of the Nasal Device during the Phase I study and its administration of Odyssey’s PRV-002 concussion drug. The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects is a huge advantage in the development of safe and efficacious treatments. Odyssey’s novel Nasal device provides that opportunity and advantage,” commented Michael Redmond, CEO of Odyssey.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in life-saving medical products and solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.
For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit our corporate social media accounts for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q
About PRV-002
PRV-002 is a synthetic non-naturally occurring neurosteroid being developed to treat central nervous system (“CNS”) injury, disease or disorder, such as, traumatic brain injury (“TBI”), especially mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
Cover |
Nov. 01, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Nov. 01, 2022 |
| Entity File Number | 000-56196 |
| Entity Registrant Name | ODYSSEY HEALTH, INC. |
| Entity Central Index Key | 0001626644 |
| Entity Tax Identification Number | 47-1022125 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 2300 West Sahara Avenue, Suite 800 - #4012 |
| Entity Address, City or Town | Las Vegas |
| Entity Address, State or Province | NV |
| Entity Address, Postal Zip Code | 89102 |
| City Area Code | 702 |
| Local Phone Number | 780-6559 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Trading Symbol | ODYY |
| Title of 12(g) Security | Common Stock ($0.001 par value) |
| Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G